Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer

[1]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[2]  R. Deberardinis,et al.  Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small cell lung cancer. , 2020, The Journal of clinical investigation.

[3]  G. Qing,et al.  Regulation of cancer cell metabolism: oncogenic MYC in the driver’s seat , 2020, Signal Transduction and Targeted Therapy.

[4]  Gabor Marth,et al.  MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. , 2020, Cancer cell.

[5]  G. Minchiotti,et al.  Proline Metabolism in Tumor Growth and Metastatic Progression , 2020, Frontiers in Oncology.

[6]  B. Perillo,et al.  ROS in cancer therapy: the bright side of the moon , 2020, Experimental & Molecular Medicine.

[7]  K. Nackaerts,et al.  Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  E. Nadal,et al.  Exploiting metabolic vulnerabilities of Non Small Cell Lung Carcinoma. , 2020, Seminars in cell & developmental biology.

[9]  J. Molina,et al.  PFKFB3 inhibition reprograms malignant pleural mesothelioma to nutrient stress-induced macropinocytosis and ER stress as independent binary adaptive responses , 2019, Cell Death & Disease.

[10]  M. Horton,et al.  Targeting metabolism to regulate immune responses in autoimmunity and cancer , 2019, Nature Reviews Drug Discovery.

[11]  N. Traverso,et al.  MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance , 2019, Oxidative medicine and cellular longevity.

[12]  Nicholas T. Ingolia,et al.  MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion , 2019, Clinical Cancer Research.

[13]  G. G. Galli,et al.  The landscape of cancer cell line metabolism , 2019, Nature Medicine.

[14]  Xun Hu,et al.  The quantitative relationship between isotopic and net contributions of lactate and glucose to the tricarboxylic acid (TCA) cycle , 2019, The Journal of Biological Chemistry.

[15]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[16]  A. Khurana,et al.  Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers , 2018, International journal of cancer.

[17]  B. Faubert,et al.  Metabolic diversity in human non-small cell lung cancer , 2014, bioRxiv.

[18]  C. Berkers,et al.  The Influence of Metabolism on Drug Response in Cancer , 2018, Front. Oncol..

[19]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[20]  R. Deberardinis,et al.  Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. , 2018, Cell metabolism.

[21]  E. Prochownik,et al.  The Role for Myc in Coordinating Glycolysis, Oxidative Phosphorylation, Glutaminolysis, and Fatty Acid Metabolism in Normal and Neoplastic Tissues , 2018, Front. Endocrinol..

[22]  G. Qing,et al.  Targeting oncogenic Myc as a strategy for cancer treatment , 2018, Signal Transduction and Targeted Therapy.

[23]  Jamey D. Young,et al.  Lactate Metabolism in Human Lung Tumors , 2017, Cell.

[24]  Yong Liu,et al.  Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism , 2017, Oncotarget.

[25]  Jing Wang,et al.  Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies , 2017, Oncotarget.

[26]  Kentaro Inamura,et al.  Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification , 2017, Front. Oncol..

[27]  M. Wangpaichitr,et al.  Exploiting ROS and metabolic differences to kill cisplatin resistant lung cancer , 2017, Oncotarget.

[28]  Kristofer C. Berrett,et al.  MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. , 2017, Cancer cell.

[29]  J. Powell,et al.  Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation , 2017, The Journal of Immunology.

[30]  N. Longo,et al.  Carnitine transport and fatty acid oxidation. , 2016, Biochimica et biophysica acta.

[31]  G. Wildey,et al.  Genomic alterations in small cell lung cancer and their clinical relevance. , 2016, Translational lung cancer research.

[32]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[33]  C. Zappa,et al.  Non-small cell lung cancer: current treatment and future advances. , 2016, Translational lung cancer research.

[34]  Jing Wang,et al.  Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer , 2016, PloS one.

[35]  Brittany Anderton,et al.  Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer , 2016, Nature Medicine.

[36]  B. Faubert,et al.  Metabolic Heterogeneity in Human Lung Tumors , 2016, Cell.

[37]  J. Locasale,et al.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses , 2015, Cell.

[38]  R. Schreiber,et al.  Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression , 2015, Cell.

[39]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[40]  Pan Tong,et al.  drexplorer: A tool to explore dose-response relationships and drug-drug interactions , 2015, Bioinform..

[41]  Qing-hua Zhou,et al.  Review of aerobic glycolysis and its key enzymes – new targets for lung cancer therapy , 2015, Thoracic cancer.

[42]  D. Felsher,et al.  MYC activation is a hallmark of cancer initiation and maintenance. , 2014, Cold Spring Harbor perspectives in medicine.

[43]  Takanori Fujita,et al.  PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer , 2013, Scientific Reports.

[44]  M. Kurtoğlu,et al.  Targeting cisplatin-resistant human tumor cells with metabolic inhibitors , 2013, Cancer Chemotherapy and Pharmacology.

[45]  David E. Muench,et al.  c-Myc and Cancer Metabolism , 2012, Clinical Cancer Research.

[46]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[47]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[48]  P. Pinton,et al.  Relation between mitochondrial membrane potential and ROS formation. , 2012, Methods in molecular biology.

[49]  Kwok-Kin Wong,et al.  Characterization of the cell of origin for small cell lung cancer , 2011, Cell cycle.

[50]  C. Thompson,et al.  Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.

[51]  T. Seyfried,et al.  Cancer as a metabolic disease , 2010, Nutrition & metabolism.

[52]  P. Storz,et al.  Reactive oxygen species in cancer , 2010, Free radical research.

[53]  O. Feron,et al.  Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  Gregor Rothe,et al.  Inhibitory effect of tumor cell-derived lactic acid on human T cells. , 2007, Blood.

[55]  Bruce J. Aronow,et al.  Chromatin Immunoprecipitation Assays Footprints in Glycolytic Genes by Evaluation of Myc E-box Phylogenetic Supplemental Material , 2004 .

[56]  A. Berns,et al.  Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.

[57]  R. Makuch,et al.  myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. , 1987, The Journal of clinical investigation.

[58]  O. Warburg,et al.  The Metabolism of Carcinoma Cells , 1925 .